Shed­ding non-core units while load­ing up on cash, Mallinck­rodt bags $250M in CD­MO sale

Mallinck­rodt may not be spin­ning off its spe­cial­ty gener­ics busi­ness any time soon, but the UK drug­mak­er is seiz­ing every chance to shed sub­sidiaries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.